Five‐year subgroup analysis of tafasitamab + lenalidomide from the phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma Meeting Abstract
| Authors: | Duell, J.; Abrisqueta, P.; Dreyling, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Maddocks, K. J.; Menne, T.; Nagy, Z.; Tournilhac, O.; Bakuli, A.; Amin, A.; Gurbanov, K.; Salles, G. |
| Abstract Title: | Five‐year subgroup analysis of tafasitamab + lenalidomide from the phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma |
| Meeting Title: | 17th International Conference on Malignant Lymphoma (ICML) |
| Journal Title: | Hematological Oncology |
| Volume: | 41 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Jun 13-17 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2023-06-01 |
| Start Page: | 439 |
| End Page: | 441 |
| Language: | English |
| DOI: | 10.1002/hon.3164_324 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 324 -- Source: Cinahl |
